Petmed Express INC 8-K filings

PetMed Express's Q4 and fiscal year 2024 results show increased sales driven by the PetCareRx acquisition, but also a net loss due to integration costs and a challenging macro environment.

PetMed Express, Inc. has announced the mutual termination of employment with Chief Financial Officer Christine Chambers, effective after a transition period.

PetMed Express has appointed Justin Mennen to its Board of Directors and updated its non-employee director compensation program.

PetMed Express has appointed Sandra Campos as its new CEO and President, effective immediately, while former CEO Matt Hulett will assist with the transition before departing on May 10, 2024.

PetMed Express reported an 11% increase in revenue for the third quarter of fiscal year 2024, driven by the acquisition of PetCareRx, and completed a financial restatement related to sales tax liabilities.

PetMed Express received a notice from Nasdaq for failing to file its quarterly report on time due to a financial restatement, potentially leading to delisting if compliance is not regained.

PetMed Express announced preliminary Q3 results with increased sales and gross profit, but will restate past financials due to errors in sales tax and deferred tax asset accounting.